Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multi-center Study to Determine the Antibody Response to 500µg G17DT Given at Weeks 0, 2, and 6 in the Treatment of Patients With Gastric Cancer

NCT02450032 is registered in ClinicalTrials.gov with Cancer Advances Inc. as lead sponsor.

NCT NCT02450032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02450032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multi-center Study to Determine the Antibody Response to 500µg G17DT Given at Weeks 0, 2, and 6 in the Treatment of Patients With Gastric Cancer
Lead sponsor
Cancer Advances Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2000
Completion date
May 31, 2001
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer